Search
Celcuity Inc
CELCAdd to Watchlist
104.620USD
+2.100+2.05%
Close 06/30, 16:00（ET）Quotes delayed by 15 min
5.05BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.05%
5 Days
+16.33%
1 Month
-21.27%
6 Months
+4.70%
Year to Date
+4.89%
1 Year
+734.29%
Key Figures
103.630Open
105.520High
1.09MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.26%Turnover Ratio
102.520Prev. Close
101.185Low
90.47MTurnover
LossP/E Static
50.20P/B
0.00%Div Yield TTM
-61.40%ROA
151.02052wk High
0.81Volume Ratio
-111.78MNet Profit
48.24MShares
-3.8973EPS TTM
0.10Beta
-275.17%ROE
10.50052wk Low
4.23%Amplitude
--Gross Margin
5.05BMarket Cap
-4.32Reward/Risk
3.84%Risk Rate
TradingKey Stock Score of Celcuity Inc
Currency: USD Updated: 2026-06-29Key Insights
Celcuity Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 113 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 160.64.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Celcuity Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Celcuity Inc Highlights
StrengthsRisks
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -26.31, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 47.21M shares, increasing 3.25% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 5.80K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.68.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
160.636
Target Price
+56.69%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Celcuity Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Celcuity Inc Info
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
Ticker SymbolCELC
CompanyCelcuity Inc
CEOSullivan (Brian F)
Websitehttps://www.celcuity.com/
Related Instruments
-2.50%
-1.79%
-0.56%
-1.22%
-0.73%
-0.57%
+0.44%
-0.86%
+0.01%
-2.42%
-0.58%
-1.64%
-0.76%
-1.77%
+1.01%
0.00%
-1.31%
+1.68%
+0.56%
+0.28%Popular Instruments
FAQs
What is the current price of Celcuity Inc (CELC)?
The current price of Celcuity Inc (CELC) is 102.52.
What is the symbol of Celcuity Inc?
The ticker symbol of Celcuity Inc is CELC.
What is the 52-week high of Celcuity Inc?
The 52-week high of Celcuity Inc is 151.02.
What is the 52-week low of Celcuity Inc?
The 52-week low of Celcuity Inc is 10.50.
What is the market capitalization of Celcuity Inc?
The market capitalization of Celcuity Inc is 5.00B.
Is Celcuity Inc (CELC) currently rated as Buy, Hold, or Sell?
According to analysts, Celcuity Inc (CELC) has an overall rating of Buy, with a price target of 160.64.
What is the Earnings Per Share (EPS TTM) of Celcuity Inc (CELC)?
The Earnings Per Share (EPS TTM) of Celcuity Inc (CELC) is -3.79.
